Why the study?
What factors are associated with the receipt of chemotherapy in elderly patients with soft tissue sarcoma?
What factors are associated with the receipt of chemotherapy in elderly patients with soft tissue sarcoma?
Consistent with clinical trials, there is minimal use of chemotherapy in elderly patients with soft tissue sarcoma in real-world practice.
Answers are grounded in this paper and cite their sources.
Minimal chemotherapy use in elderly STS confirms trial consistency; leaves open factors guiding real-world decisions.
Adjuvant chemotherapy for soft tissue sarcoma (STS) remains controversial while improvement in survival has never been conclusively demonstrated for metastatic STS. We identified individuals in SEER-Medicare with resected or metastatic STS, 1991-2007. Of 2,382 patients with resected STS, 106 (4.5%) received chemotherapy. High tumor grade, larger tumor size, and malignant fibrous histiocytoma subtype were associated with chemotherapy receipt. Of 365 patients with metastatic STS, 118 (32.4%) received chemotherapy. Younger age, fewer comorbidities, and being married were associated with chemotherapy receipt. Consistent with clinical trials, we found minimal use of chemotherapy. Clinical factors were associated with chemotherapy receipt in nonmetastatic STS.
No takes yet. Share an insight, caveat, or question.
Matushansky et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: